Stelara IV coverage changes coming

Beginning July 1, Stelara® IV will be removed from coverage under the medical benefit for our commercial and individual members. This change will only impact members who aren’t currently being treated with Stelara IV. Members already approved for Stelara IV under the medical benefit will remain covered.

Formulary alternatives

Stelara biosimilars, Yesintek™ and Selarsdi™, were added to formulary on April 1. These drugs are effective, safe and have undergone the same rigorous testing and FDA approval process.

What do you need to do?

We recommend prescribing Yesintek or Selarsdi for your patients seeking treatment for symptoms of plaque psoriasis, psoriatic arthritis, Crohn's disease and/or ulcerative colitis.